drugset / Trial / NCT06548347
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.
Timeline
- Start
- 2024-09-10
- Primary completion
- 2024-12-31
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | 60 mg | Oral |
| Subject | Linperlisib | Small molecule | 80 mg | Oral |